Overview


According to FutureWise analysis the market for acute heart failure (ahf) therapeutics in 2023 is US$ 0.68 billion, and is expected to reach US$ 3.33 billion by 2031 at a CAGR of 21.9%.

Heart failure is a medical condition where the heart is unable to efficiently circulate blood throughout the body, leading to a decrease in cardiac output. Acute heart failure (AHF) or acute decompensated heart failure (ADHF) is when symptoms suddenly appear or worsen rapidly. This is a critical and potentially dangerous situation that demands immediate medical attention. It's important to seek early and appropriate treatment as it can affect the outcome of the condition.AHF can be triggered by one or more factors in the presence of subsequent structural or functional cardiac dysfunction. However, in some cases, heart failure can emerge directly from the onset of a new cardiac dysfunction, typically arising from acute coronary syndrome.

Current treatment of AHF is primarily symptomatic, centered on anti-congestive drugs, at best, customized according to the initial hemodynamic state with little regard to the subsequent pathophysiological specificities. As a result, AHF is still associated with high mortality and rehospitalisation rates. There is a notable lack in providing personalized care in hospitals, such as administering treatments that address the root causes and providing ongoing therapy after discharge to enhance long-term results.

FutureWise Market Research has published a report that provides an insightful analysis acute heart failure (afh) therapeutics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, acute heart failure (afh) therapeutics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Novartis AG
  • Cardiorentis AG
  • Bristol-Myers Squibb Company
  • Amgen Inc
  • Bayer AG
  • Cytokinetics, Inc
  • Ono Pharmaceutical Co., Ltd
  • Pfizer Inc
  • CVie Therapeutics Limited
  • Merck and Co
  • Orion Corporation
  • PhaseBio Pharmaceuticals, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Category

  • Angiotensin-Converting Enzyme (ACE) Inhibitors
    • Captopril (Capoten)
    • Enalapril (Vasotec)
    • Fosinopril (Monopril)
    • Lisinopril (Prinivil, Zestril)
    • Perindopril (Aceon)
    • Quinapril (Accupril)
    • Ramipril (Altace)
    • Others
  • Angiotensin II Receptor Blockers
    • Candesartan (Atacand)
    • Losartan (Cozaar)
    • Valsartan (Diovan)
  • Angiotensin-Receptor Neprilysin Inhibitors (ARNIs)
    • Sacubitril/valsartan
  • If Channel Blocker
    • Ivabradine (Corlanor)
  • Beta Blockers
    • Bisoprolol (Zebeta)
    • Metoprolol Succinate (Toprol XL)
    • Carvedilol (Coreg)
    • Others
  • Aldosterone Antagonists
    • Spironolactone (Aldactone)
    • Eplerenone (Inspra)
    • Diuretics
    • Furosemide (Lasix)
    • Bumetanide (Bumex)
    • Torsemide (Demadex)
    • Chlorothiazide (Diuril)
  • Amiloride (Midamor Chlorthalidone (Hygroton)
    • Hydrochlorothiazide or HCTZ (Esidrix, Hydrodiuril)
    • Others
  • Anticoagulants (Blood Thinners)
    • Cholesterol Lowering Drugs (Statins)
    • Digoxin

By Disorder Type

  • Right-sided Heart Failure
  • Left-sided Heart Failure
    • Systolic Failure
    • Diastolic Failure
  • Congestive Heart Failure

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Acute Heart Failure (AHF) Therapeutics Market By Drug Category, By Disorder Type, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Disorder Type launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Acute Heart Failure (AHF) Therapeutics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Heart Failure (AHF) Therapeutics Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Acute Heart Failure (AHF) Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Acute Heart Failure (AHF) Therapeutics Market, By Drug Category Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Angiotensin-Converting Enzyme (ACE) Inhibitors
         1.1. Captopril (Capoten)
         1.2. Enalapril (Vasotec)
         1.3. Fosinopril (Monopril)
         1.4. Lisinopril (Prinivil, Zestril)
         1.5. Perindopril (Aceon)
         1.6. Quinapril (Accupril)
         1.7. Ramipril (Altace)
         1.8. Others
        2. Angiotensin II Receptor Blockers
         2.1. Candesartan (Atacand)
         2.2. Losartan (Cozaar)
         2.3. Valsartan (Diovan)
        3. Angiotensin-Receptor Neprilysin Inhibitors (ARNIs)
         3.1. Sacubitril/valsartan
        4. If Channel Blocker
         4.1. Ivabradine (Corlanor)
        5. Beta Blockers
         5.1. Bisoprolol (Zebeta)
         5.2. Metoprolol Succinate (Toprol XL)
         5.3. Carvedilol (Coreg)
         5.4. Others
        6. Aldosterone Antagonists
         6.1. Spironolactone (Aldactone)
         6.2. Eplerenone (Inspra)
         6.3. Diuretics
         6.4. Furosemide (Lasix)
         6.5. Bumetanide (Bumex)
         6.6. Torsemide (Demadex)
         6.7. Chlorothiazide (Diuril)
        7. Amiloride (Midamor Chlorthalidone (Hygroton)
         7.1. Hydrochlorothiazide or HCTZ (Esidrix, Hydrodiuril)
         7.2. Others
        8. Anticoagulants (Blood Thinners)
         8.1. Cholesterol Lowering Drugs (Statins)
         8.2. Digoxin

  • 8.   Global Acute Heart Failure (AHF) Therapeutics Market, By Disorder Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Right-sided Heart Failure
        2. Left-sided Heart Failure
         2.1. Systolic Failure
         2.2. Diastolic Failure
        3. Congestive Heart Failure

  • 9.   Global Acute Heart Failure (AHF) Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 10.   North America Acute Heart Failure (AHF) Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Acute Heart Failure (AHF) Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Acute Heart Failure (AHF) Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Acute Heart Failure (AHF) Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Disorder Types Offered and Financial Layouts)
    •   1. Novartis AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Cardiorentis AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bristol-Myers Squibb Company
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Amgen Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bayer AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Cytokinetics, Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Ono Pharmaceutical Co., Ltd
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Pfizer Inc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. CVie Therapeutics Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Merck and Co
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Orion Corporation
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. PhaseBio Pharmaceuticals, Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients